AOC1: Potential Drug Target and Biomarker for Multiple Diseases

Target Name: AOC1

NCBI ID: G26

AOC1

AOC1: Potential Drug Target and Biomarker for Multiple Diseases

AOC1 (AOC1 variant 2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, lungs, and liver. It is a member of the AOC1 gene family, which is known for its role in cell signaling and inflammation.

One of the unique aspects of AOC1 is its ability to interact with multiple signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. This makes AOC1 a promising target for drug development, as it is possible to target multiple pathways with a single drug.

In addition to its potential as a drug target, AOC1 is also a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This makes it an attractive target for researchers to study the role of AOC1 in these diseases, as well as to identify new diagnostic tests and biomarkers.

The AOC1 protein has been shown to play a role in several cellular processes, including cell signaling, cell division, and inflammation. It is a key regulator of the TGF-β pathway, which is involved in cell growth, differentiation, and inflammation.

AOC1 has been shown to interact with the protein SMAD4, which is a negative regulator of the TGF-β pathway. This interaction between AOC1 and SMAD4 suggests that AOC1 may be a negative regulator of TGF-β signaling.

In addition to its role in TGF-β signaling, AOC1 is also involved in cell division and cell cycle regulation. It has been shown to interact with the protein p21, which is a negative regulator of the p53 tumor suppressor gene. This interaction between AOC1 and p21 suggests that AOC1 may be involved in regulating cell cycle progression and apoptosis.

AOC1 is also involved in inflammation, as it has been shown to interact with several signaling pathways that are involved in inflammation. It has been shown to interact with the protein NF-kappa-B, which is involved in inflammation and immune response.

In addition to its role in inflammation, AOC1 is also involved in cell signaling and cell survival. It has been shown to interact with several signaling pathways, including the PI3K/Akt pathway and the NF-kappa-B pathway. This suggests that AOC1 may be involved in regulating cellular signaling and survival.

Given its involvement in multiple cellular processes, AOC1 is an attractive target for drug development. However, the development of new drugs that specifically target AOC1 will be challenging, as it is possible to target multiple pathways with a single drug.

In addition to its potential as a drug target, AOC1 is also a potential biomarker for several diseases. For example, it has been shown to be involved in the development of cancer, neurodegenerative diseases, and autoimmune diseases. This makes it important for researchers to study the role of AOC1 in these diseases, as well as to identify new diagnostic tests and biomarkers.

Overall, AOC1 is a protein that is involved in multiple cellular processes and has been shown to play a role in several diseases. Its potential as a drug target and biomarker make it an attractive target for research into the role of AOC1 in these diseases. Further research is needed to understand the full role of AOC1 in cellular processes and its potential as a drug and biomarker.

Protein Name: Amine Oxidase Copper Containing 1

Functions: Catalyzes the degradation of compounds such as putrescine, histamine, spermine, and spermidine, substances involved in allergic and immune responses, cell proliferation, tissue differentiation, tumor formation, and possibly apoptosis. Placental DAO is thought to play a role in the regulation of the female reproductive function

The "AOC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AOC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets